Download PDF
CC BY 4.0 · World J Nucl Med 2024; 23(01): 033-042
DOI: 10.1055/s-0044-1779282
Original Article

Predictive Value of Corrected 18F-FDG PET/CT Baseline Parameters for Primary DLBCL Prognosis: A Single-center Study

Min Li   *
1   Department of Nuclear Medicine, Tai'an Central Hospital of Qingdao University, Tai'an, Shandong, People's Republic of China
,
Jianpeng Liu   *
2   Department of Radiology, Huashan Hospital of Fudan University, Shanghai, People's Republic of China
,
Fangfei Liu
3   Department of Nuclear Medicine, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, People's Republic of China
,
Rongbin Lv
1   Department of Nuclear Medicine, Tai'an Central Hospital of Qingdao University, Tai'an, Shandong, People's Republic of China
,
Haowei Bai
1   Department of Nuclear Medicine, Tai'an Central Hospital of Qingdao University, Tai'an, Shandong, People's Republic of China
,
Shuyong Liu
3   Department of Nuclear Medicine, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, People's Republic of China
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective The purpose of this study was to evaluate the prognostic significance of corrected baseline metabolic parameters in fluorodeoxyglucose positron emission tomography imaging (18F-FDG PET/CT) for 3-year progression-free survival (PFS) in patients with primary diffuse large B cell lymphoma (DLBCL).

Patients and Methods Retrospective clinical and pathological data were collected for 199 patients of DLBCL diagnosed between January 2018 and January 2021. All patients underwent 18F-FDG PET/CT scans without any form of treatment. The corrected maximum standardized uptake value (corSUVmax), corrected mean standardized uptake value (corSUVmean), corrected whole-body tumor metabolic volume sum (corMTVsum), and corrected total lesion glycolysis of whole body (corTLGtotal) were corrected using the SUVmean in a 1-cm diameter mediastinal blood pool (MBP) from the descending thoracic aorta of patients. Kaplan–Meier survival curves and Cox regression were used to examine the predictive significance of corrected baseline metabolic parameters on 3-year PFS of patients. The incremental values of corrected baseline metabolic parameters were evaluated by using Harrell's C-indices, receiver operating characteristic, and Decision Curve Analysis.

Results The multivariate analysis revealed that only the National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and corMTVsum had an effect on 3-year PFS of patients (p < 0.05, respectively). The Kaplan–Meier survival analysis demonstrated significant differences in PFS between the risk groups classified by corSUVsum, corMTVsum, and corTLGtotal (log-rank test, p < 0.05). The predictive model composed of corMTVsum and corTLGtotal surpasses the predictive performance of the model incorporating MTVsum and TLGtotal. The optimal performance was observed when corMTVsum was combined with NCCN-IPI, resulting in a Harrell's C index of 0.785 and area under the curve values of 0.863, 0.891, and 0.947 for the 1-, 2-, and 3-year PFS rates, respectively.

Conclusion The corMTVsum offers significant prognostic value for patients with DLBCL. Furthermore, the combination of corMTVsum with the NCCN-IPI can provide an accurate prediction of the prognosis.

Keywords

18F-FDG PET/CT - DLBCL - progression-free survival - NCCN-IPI - prognosis

* These authors contributed equally to this work and retain the first authorship.




Publication History

Article published online:
13 February 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010; 60 (06) 393-408
    PubMedGoogle Scholar
  • 2 Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology (Am Soc Hematol Educ Program) 2011; 498-505
    CrossrefPubMedGoogle Scholar
  • 3 Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 2015; 125 (01) 22-32
    CrossrefPubMedGoogle Scholar
  • 4 International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329 (14) 987-994
    CrossrefPubMedGoogle Scholar
  • 5 Ziepert M, Hasenclever D, Kuhnt E. et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. [published correction appears in J Clin Oncol 2011 Feb 20;29(6):779] J Clin Oncol 2010; 28 (14) 2373-2380
    CrossrefPubMedGoogle Scholar
  • 6 Zhou Z, Sehn LH, Rademaker AW. et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123 (06) 837-842
    CrossrefPubMedGoogle Scholar
  • 7 Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk 2014; 14 (06) 460-467.e2
    CrossrefPubMedGoogle Scholar
  • 8 Horn H, Ziepert M, Becher C. et al; German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121 (12) 2253-2263
    CrossrefPubMedGoogle Scholar
  • 9 Cheson BD, Pfistner B, Juweid ME. et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (05) 579-586
    CrossrefPubMedGoogle Scholar
  • 10 Juweid ME, Stroobants S, Hoekstra OS. et al; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25 (05) 571-578
    CrossrefPubMedGoogle Scholar
  • 11 Cheson BD, Fisher RI, Barrington SF. et al; Alliance, Australasian Leukaemia and Lymphoma Group, ; Eastern Cooperative Oncology Group, ; European Mantle Cell Lymphoma Consortium, ; Italian Lymphoma Foundation, ; European Organisation for Research, ; Treatment of Cancer/Dutch Hemato-Oncology Group, ; Grupo Español de Médula Ósea, ; German High-Grade Lymphoma Study Group, ; German Hodgkin's Study Group, ; Japanese Lymphorra Study Group, ; Lymphoma Study Association, ; NCIC Clinical Trials Group, ; Nordic Lymphoma Study Group, ; Southwest Oncology Group, ; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27) 3059-3068
    CrossrefPubMedGoogle Scholar
  • 12 Gupta N, Singh N. To determine the prognostic significance of 18-fluorodeoxyglucose positron emission tomography/computed tomography scan-derived parameters (total lesion glycolysis and metabolic tumor volume) in patients of diffuse large B-cell lymphoma with only nodal involvement. Indian J Nucl Med 2020; 35 (02) 100-104
    CrossrefPubMedGoogle Scholar
  • 13 Guzmán Ortiz S, Mucientes Rasilla J, Vargas Núñez JA, Royuela A, Navarro Matilla B, Mitjavila Casanovas M. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with 18F-FDG PET/CT, in patients with diffuse large cell B-cell lymphoma. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2020; 39 (06) 340-346
    PubMedGoogle Scholar
  • 14 Ceriani L, Martelli M, Zinzani PL. et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood 2015; 126 (08) 950-956
    CrossrefPubMedGoogle Scholar
  • 15 Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget 2016; 7 (50) 83544-83553
    CrossrefPubMedGoogle Scholar
  • 16 Meignan M, Cottereau AS, Versari A. et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 2016; 34 (30) 3618-3626
    CrossrefPubMedGoogle Scholar
  • 17 Shagera QA, Cheon GJ, Koh Y. et al. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging 2019; 46 (07) 1417-1427
    CrossrefPubMedGoogle Scholar
  • 18 Sasanelli M, Meignan M, Haioun C. et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 2014; 41 (11) 2017-2022
    CrossrefPubMedGoogle Scholar
  • 19 Gallicchio R, Mansueto G, Simeon V. et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol 2014; 92 (05) 382-389
    CrossrefPubMedGoogle Scholar
  • 20 Meignan M, Itti E, Bardet S. et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol 2009; 27 (16) 2739-2741
    CrossrefPubMedGoogle Scholar
  • 21 Chiaravalloti A, Danieli R, Abbatiello P. et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2014; 41 (06) 1123-1132
    PubMedGoogle Scholar
  • 22 Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 2017; 44 (suppl 1): 97-110
    CrossrefPubMedGoogle Scholar
  • 23 Cysouw MCF, Kramer GM, Hoekstra OS. et al. Accuracy and precision of partial-volume correction in oncological PET/CT studies. J Nucl Med 2016; 57 (10) 1642-1649
    CrossrefPubMedGoogle Scholar
  • 24 Hoetjes NJ, van Velden FH, Hoekstra OS. et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging 2010; 37 (09) 1679-1687
    CrossrefPubMedGoogle Scholar
  • 25 Taghvaei R, Zadeh MZ, Sirous R. et al. Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy. Am J Nucl Med Mol Imaging 2018; 8 (06) 407-414
    PubMedGoogle Scholar
  • 26 Škor O, Bicanová L, Wolfesberger B. et al. Are B-symptoms more reliable prognostic indicators than substage in canine nodal diffuse large B-cell lymphoma. Vet Comp Oncol 2021; 19 (01) 201-208
    CrossrefPubMedGoogle Scholar
  • 27 Adams HJ, de Klerk JM, Fijnheer R. et al. Prognostic value of anemia and C-reactive protein levels in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2015; 15 (11) 671-679
    CrossrefPubMedGoogle Scholar
  • 28 Wu S, Zhou Y, Hua HY. et al. Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma. BMC Cancer 2018; 18 (01) 997
    CrossrefPubMedGoogle Scholar
  • 29 Kim DJ, Kim T, Jeong JY. et al. Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma. Int J Hematol 2020; 111 (04) 559-566
    CrossrefPubMedGoogle Scholar